Taken together with the similar study of MOv18 IgE, the administration of IgE antibodies targeted against tumour-associated antigens did not lead to any severe adverse events, particularly anaphylactic reactions, in immunologically relevant rat models. The gene discussed is IGHE; the disease is neoplasm.